© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 7, 504-513,
April 3, 2002
© 2002 Oxford University Press
ARTICLE |
Modulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228
Affiliation of authors: X. Yu, Z. S. Guo, D. M. Nguyen, G. A. Chen, D. S. Schrump (Thoracic Oncology Section, Surgery Branch), M. G. Marcu, L. Neckers (Tumor Cell Biology Section), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Correspondence to: David S. Schrump, M.D., Thoracic Oncology Section, Surgery Branch, Bldg. 10, Rm. 2B-07, 10 Center Dr., Bethesda, MD 20892–1502 (e-mail: David_Schrump{at}nih.gov).
Background: Histone deacetylases (HDACs) modulate chromatin structure by regulating acetylation of core histone proteins. HDAC inhibitors, such as depsipeptide FR901228 (FK228), induce growth arrest and apoptosis in a variety of human cancer cells by mechanisms that cannot be attributed solely to histone acetylation. This study evaluated the mechanisms by which FK228 mediates apoptosis in non-small-cell lung cancer (NSCLC) cells. Methods: Proliferation and apoptosis were assessed in a panel of NSCLC cell lines that vary in the expression of the growth-regulating proteins p53, pRb, and K-Ras treated with a clinically relevant dose of FK228 (25 ng/mL). Western blot and immunoprecipitation techniques were used to analyze expression of cell-cycle proteins (cyclin A, cyclin E, p53, and p21), signaling-related proteins (ErbB1, ErbB2, and Raf-1), activity of extracellular signal-regulated kinase 1 and 2 (ERK1/2), binding of mutant p53 and Raf-1 to heat shock protein (Hsp)90, and acetylation of Hsp90. Results: FK228 treatment inhibited growth and induced apoptosis in NSCLC cells expressing wild-type or mutant p53. FK228 treatment led to altered expression of cyclin A, cyclin E, and p21, and to reduced expression of mutant, but not wild-type, p53. FK228-treated cells also were depleted of ErbB1, ErbB2, and Raf-1 proteins, and exhibited lower ERK1/2 activity. FK228 treatment also inhibited the binding of mutant p53 and Raf-1 to Hsp90; this inhibition was associated with acetylation of Hsp90. Conclusions: FK228 depletes the levels of several oncoproteins that are normally stabilized by binding to Hsp90 in cancer cells. The resulting ability of FK228 to diminish signal transduction via pathways involving Raf-1 and ERK may contribute to the potency and specificity of this novel antitumor agent.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Q. Li, D. L. Bartlett, M. C. Gorry, M. E. O'Malley, and Z. S. Guo Three Epigenetic Drugs Up-Regulate Homeobox Gene Rhox5 in Cancer Cells through Overlapping and Distinct Molecular Mechanisms Mol. Pharmacol., November 1, 2009; 76(5): 1072 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Molife, G. Attard, P. C. Fong, V. Karavasilis, A. H. M. Reid, S. Patterson, C. E. Riggs Jr, C. Higano, W. M. Stadler, W. McCulloch, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC) Ann. Onc., July 16, 2009; (2009) mdp270v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. D. Kekatpure, A. J. Dannenberg, and K. Subbaramaiah HDAC6 Modulates Hsp90 Chaperone Activity and Regulates Activation of Aryl Hydrocarbon Receptor Signaling J. Biol. Chem., March 20, 2009; 284(12): 7436 - 7445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Matsubara, M. Watanabe, T. Imai, Y. Yui, Y. Mizushima, Y. Hiraumi, Y. Kamitsuji, K.-i. Watanabe, K. Nishijo, J. Toguchida, et al. Involvement of Extracellular Signal-Regulated Kinase Activation in Human Osteosarcoma Cell Resistance to the Histone Deacetylase Inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone] J. Pharmacol. Exp. Ther., March 1, 2009; 328(3): 839 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-L. Cha, M.-J. Chuang, S.-T. Wu, G.-H. Sun, S.-Y. Chang, D.-S. Yu, S.-M. Huang, S. K.-H. Huan, T.-C. Cheng, T.-T. Chen, et al. Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells Clin. Cancer Res., February 1, 2009; 15(3): 840 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. de Bono, R. Kristeleit, A. Tolcher, P. Fong, S. Pacey, V. Karavasilis, M. Mita, H. Shaw, P. Workman, S. Kaye, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors Clin. Cancer Res., October 15, 2008; 14(20): 6663 - 6673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Song, R. Chaerkady, A. C. Tan, E. Garcia-Garcia, A. Nalli, A. Suarez-Gauthier, F. Lopez-Rios, X. F. Zhang, A. Solomon, J. Tong, et al. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer Mol. Cancer Ther., October 1, 2008; 7(10): 3275 - 3284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Wandinger, K. Richter, and J. Buchner The Hsp90 Chaperone Machinery J. Biol. Chem., July 4, 2008; 283(27): 18473 - 18477. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wang, M. J. Powell, V. M. Popov, and R. G. Pestell Acetylation in Nuclear Receptor Signaling and the Role of Sirtuins Mol. Endocrinol., March 1, 2008; 22(3): 539 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fan, J. Stanfield, Y. Guo, J. A. Karam, E. Frenkel, X. Sun, and J.-T. Hsieh Effect of Trans-2,3-Dimethoxycinnamoyl Azide on Enhancing Antitumor Activity of Romidepsin on Human Bladder Cancer Clin. Cancer Res., February 15, 2008; 14(4): 1200 - 1207. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Schrump, M. R. Fischette, D. M. Nguyen, M. Zhao, X. Li, T. F. Kunst, A. Hancox, J. A. Hong, G. A. Chen, E. Kruchin, et al. Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin Clin. Cancer Res., January 1, 2008; 14(1): 188 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D.-A. Tran, T. P. Marmo, A. A. Salam, S. Che, E. Finkelstein, R. Kabarriti, H. S. Xenias, R. Mazitschek, C. Hubbert, Y. Kawaguchi, et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions J. Cell Sci., April 15, 2007; 120(8): 1469 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maloney, P. A. Clarke, S. Naaby-Hansen, R. Stein, J.-O. Koopman, A. Akpan, A. Yang, M. Zvelebil, R. Cramer, L. Stimson, et al. Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Cancer Res., April 1, 2007; 67(7): 3239 - 3253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Choudhary and H.-C. R. Wang Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells Mol. Cancer Ther., March 1, 2007; 6(3): 1099 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hardcastle, P. Tomlin, C. Norris, J. Richards, M. Cordwell, K. Boxall, M. Rowlands, K. Jones, I. Collins, E. McDonald, et al. A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation Mol. Cancer Ther., March 1, 2007; 6(3): 1112 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yu, B. B. Friday, J.-P. Lai, A. McCollum, P. Atadja, L. R. Roberts, and A. A. Adjei Abrogation of MAPK and Akt Signaling by AEE788 Synergistically Potentiates Histone Deacetylase Inhibitor-Induced Apoptosis through Reactive Oxygen Species Generation Clin. Cancer Res., February 15, 2007; 13(4): 1140 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Marrocco, W. D. Tilley, T. Bianco-Miotto, A. Evdokiou, H. I. Scher, R. A. Rifkind, P. A. Marks, V. M. Richon, and L. M. Butler Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation Mol. Cancer Ther., January 1, 2007; 6(1): 51 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Lee, J.-H. Park, Y. Jung, J.-H. Kim, H.-S. Jong, T.-Y. Kim, and Y.-J. Bang Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells Mol. Cancer Ther., December 1, 2006; 5(12): 3085 - 3095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V Powers and P. Workman Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S125 - S135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Fath, X. Kong, D. Liang, Z. Lin, A. Chou, Y. Jiang, J. Fang, J. Caro, and N. Sang Histone Deacetylase Inhibitors Repress the Transactivation Potential of Hypoxia-inducible Factors Independently of Direct Acetylation of HIF-{alpha} J. Biol. Chem., May 12, 2006; 281(19): 13612 - 13619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sankaranarayanapillai, W. P. Tong, D. S. Maxwell, A. Pal, J. Pang, W. G. Bornmann, J. G. Gelovani, and S. M. Ronen Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy Mol. Cancer Ther., May 1, 2006; 5(5): 1325 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhao, S. Lu, L. Wu, G. Chai, H. Wang, Y. Chen, J. Sun, Y. Yu, W. Zhou, Q. Zheng, et al. Acetylation of p53 at Lysine 373/382 by the Histone Deacetylase Inhibitor Depsipeptide Induces Expression of p21Waf1/Cip1. Mol. Cell. Biol., April 1, 2006; 26(7): 2782 - 2790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Rosato, S. C. Maggio, J. A. Almenara, S. G. Payne, P. Atadja, S. Spiegel, P. Dent, and S. Grant The Histone Deacetylase Inhibitor LAQ824 Induces Human Leukemia Cell Death through a Process Involving XIAP Down-Regulation, Oxidative Injury, and the Acid Sphingomyelinase-Dependent Generation of Ceramide Mol. Pharmacol., January 1, 2006; 69(1): 216 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Rosato, J. A. Almenara, S. C. Maggio, P. Atadja, R. Craig, J. Vrana, P. Dent, and S. Grant Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells Mol. Cancer Ther., November 1, 2005; 4(11): 1772 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. M. Murphy, Y. Morishima, J. J. Kovacs, T.-P. Yao, and W. B. Pratt Regulation of the Dynamics of hsp90 Action on the Glucocorticoid Receptor by Acetylation/Deacetylation of the Chaperone J. Biol. Chem., October 7, 2005; 280(40): 33792 - 33799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Chung, S. Lee, E. A. Sausville, Q. Ryan, J. E. Karp, I. Gojo, W. G. Telford, M.-J. Lee, H. S. Kong, and J. B. Trepel Histone Deacetylase Inhibitor Pharmacodynamic Analysis by Multiparameter Flow Cytometry Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 397 - 406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Banerji, M. Walton, F. Raynaud, R. Grimshaw, L. Kelland, M. Valenti, I. Judson, and P. Workman Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models Clin. Cancer Res., October 1, 2005; 11(19): 7023 - 7032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Beeram, A. Patnaik, and E. K. Rowinsky Raf: A Strategic Target for Therapeutic Development Against Cancer J. Clin. Oncol., September 20, 2005; 23(27): 6771 - 6790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Chen, S. Meng, H. Wang, P. Bali, W. Bai, B. Li, P. Atadja, K. N. Bhalla, and J. Wu Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824 Mol. Cancer Ther., September 1, 2005; 4(9): 1311 - 1319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bali, M. Pranpat, R. Swaby, W. Fiskus, H. Yamaguchi, M. Balasis, K. Rocha, H.-G. Wang, V. Richon, and K. Bhalla Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2 Clin. Cancer Res., September 1, 2005; 11(17): 6382 - 6389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Blagosklonny, S. Trostel, G. Kayastha, Z. N. Demidenko, L. T. Vassilev, L. Y. Romanova, S. Bates, and T. Fojo Depletion of Mutant p53 and Cytotoxicity of Histone Deacetylase Inhibitors Cancer Res., August 15, 2005; 65(16): 7386 - 7392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bali, M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, et al. Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90: A NOVEL BASIS FOR ANTILEUKEMIA ACTIVITY OF HISTONE DEACETYLASE INHIBITORS J. Biol. Chem., July 22, 2005; 280(29): 26729 - 26734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. N. Bhalla Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Peng, X. Guo, S. C. Borkan, A. Bharti, Y. Kuramochi, S. Calderwood, and D. B. Sawyer Heat Shock Protein 90 Stabilization of ErbB2 Expression Is Disrupted by ATP Depletion in Myocytes J. Biol. Chem., April 1, 2005; 280(13): 13148 - 13152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bai, J. Sui, A. Demirjian, C. M. Vollmer Jr., W. Marasco, and M. P. Callery Predominant Bcl-XL Knockdown Disables Antiapoptotic Mechanisms: Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Based Triple Chemotherapy Overcomes Chemoresistance in Pancreatic Cancer Cells In vitro Cancer Res., March 15, 2005; 65(6): 2344 - 2352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rahmani, E. Reese, Y. Dai, C. Bauer, S. G. Payne, P. Dent, S. Spiegel, and S. Grant Coadministration of Histone Deacetylase Inhibitors and Perifosine Synergistically Induces Apoptosis in Human Leukemia Cells through Akt and ERK1/2 Inactivation and the Generation of Ceramide and Reactive Oxygen Species Cancer Res., March 15, 2005; 65(6): 2422 - 2432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. WORKMAN Drugging the Cancer Kinome: Progress and Challenges in Developing Personalized Molecular Cancer Therapeutics Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 499 - 515. [Abstract] [PDF]
|
|
|
|
 |
|
 J. B. Maxhimer, R. M. Reddy, J. Zuo, G. W. Cole Jr, D. S. Schrump, and D. M. Nguyen Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C) J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 53 - 63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Doi, H. Soda, M. Oka, J. Tsurutani, T. Kitazaki, Y. Nakamura, M. Fukuda, Y. Yamada, S. Kamihira, and S. Kohno The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells Mol. Cancer Ther., November 1, 2004; 3(11): 1397 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Gallagher and E.A. Tallant Inhibition of human lung cancer cell growth by angiotensin-(1-7) Carcinogenesis, November 1, 2004; 25(11): 2045 - 2052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Cohen and T.-P. Yao AcK-knowledge Reversible Acetylation Sci. Signal., August 10, 2004; 2004(245): pe42 - pe42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bagatell and L. Whitesell Altered Hsp90 function in cancer: A unique therapeutic opportunity Mol. Cancer Ther., August 1, 2004; 3(8): 1021 - 1030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Denlinger, M. D. Keller, M. W. Mayo, R. M. Broad, and D. R. Jones Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1078 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Maggio, R. R. Rosato, L. B. Kramer, Y. Dai, M. Rahmani, D. S. Paik, A. C. Czarnik, S. G. Payne, S. Spiegel, and S. Grant The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells Cancer Res., April 1, 2004; 64(7): 2590 - 2600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nguyen, W. D. Schrump, G. A. Chen, W. Tsai, P. Nguyen, J. B. Trepel, and D. S. Schrump Abrogation of p21 Expression by Flavopiridol Enhances Depsipeptide-Mediated Apoptosis in Malignant Pleural Mesothelioma Cells Clin. Cancer Res., March 1, 2004; 10(5): 1813 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Blank, M. Mandel, Y. Keisari, D. Meruelo, and G. Lavie Enhanced Ubiquitinylation of Heat Shock Protein 90 as a Potential Mechanism for Mitotic Cell Death in Cancer Cells Induced with Hypericin Cancer Res., December 1, 2003; 63(23): 8241 - 8247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rahmani, C. Yu, Y. Dai, E. Reese, W. Ahmed, P. Dent, and S. Grant Coadministration of the Heat Shock Protein 90 Antagonist 17-Allylamino- 17-demethoxygeldanamycin with Suberoylanilide Hydroxamic Acid or Sodium Butyrate Synergistically Induces Apoptosis in Human Leukemia Cells Cancer Res., December 1, 2003; 63(23): 8420 - 8427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Yu, M. Rahmani, D. Conrad, M. Subler, P. Dent, and S. Grant The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571 Blood, November 15, 2003; 102(10): 3765 - 3774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Swede, Y. Dong, M. Reid, J. Marshall, and C. Ip Cell Cycle Arrest Biomarkers in Human Lung Cancer Cells After Treatment with Selenium in Culture Cancer Epidemiol. Biomarkers Prev., November 1, 2003; 12(11): 1248 - 1252. [Abstract] [Full Text]
|
|
|
|
|
|
L. Fuino, P. Bali, S. Wittmann, S. Donapaty, F. Guo, H. Yamaguchi, H.-G. Wang, P. Atadja, and K. Bhalla Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B Mol. Cancer Ther., October 1, 2003; 2(10): 971 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nimmanapalli, L. Fuino, P. Bali, M. Gasparetto, M. Glozak, J. Tao, L. Moscinski, C. Smith, J. Wu, R. Jove, et al. Histone Deacetylase Inhibitor LAQ824 Both Lowers Expression and Promotes Proteasomal Degradation of Bcr-Abl and Induces Apoptosis of Imatinib Mesylate-sensitive or -refractory Chronic Myelogenous Leukemia-Blast Crisis Cells Cancer Res., August 15, 2003; 63(16): 5126 - 5135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Nguyen, W. D. Schrump, W. S. Tsai, A. Chen, J. H. Stewart IV, F. Steiner, and D. S. Schrump Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling pathway J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 1132 - 1142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Nimmanapalli, L. Fuino, C. Stobaugh, V. Richon, and K. Bhalla Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells Blood, April 15, 2003; 101(8): 3236 - 3239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hemminki, A. Kanerva, B. Liu, M. Wang, R. D. Alvarez, G. P. Siegal, and D. T. Curiel Modulation of Coxsackie-Adenovirus Receptor Expression for Increased Adenoviral Transgene Expression Cancer Res., February 15, 2003; 63(4): 847 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Furumai, A. Matsuyama, N. Kobashi, K.-H. Lee, M. Nishiyama, H. Nakajima, A. Tanaka, Y. Komatsu, N. Nishino, M. Yoshida, et al. FK228 (Depsipeptide) as a Natural Prodrug That Inhibits Class I Histone Deacetylases Cancer Res., September 1, 2002; 62(17): 4916 - 4921. [Abstract] [Full Text] [PDF]
|
|